These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 30066212)

  • 1. Tissue and Bronchoalveolar Lavage Biomarkers in Idiopathic Pulmonary Fibrosis Patients on Pirfenidone.
    Ronan N; Bennett DM; Khan KA; McCarthy Y; Dahly D; Bourke L; Chelliah A; Cavazza A; O'Regan K; Moloney F; Plant BJ; Henry MT
    Lung; 2018 Oct; 196(5):543-552. PubMed ID: 30066212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice.
    Okuda R; Hagiwara E; Baba T; Kitamura H; Kato T; Ogura T
    Respir Med; 2013 Sep; 107(9):1431-7. PubMed ID: 23849626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone.
    Ikeda K; Shiratori M; Chiba H; Nishikiori H; Yokoo K; Saito A; Hasegawa Y; Kuronuma K; Otsuka M; Yamada G; Takahashi H
    Respir Med; 2017 Oct; 131():184-191. PubMed ID: 28947028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
    Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
    PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan.
    Ikeda K; Chiba H; Nishikiori H; Azuma A; Kondoh Y; Ogura T; Taguchi Y; Ebina M; Sakaguchi H; Miyazawa S; Suga M; Sugiyama Y; Nukiwa T; Kudoh S; Takahashi H;
    Respir Res; 2020 Nov; 21(1):316. PubMed ID: 33256760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
    Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H
    BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
    Nathan SD; Costabel U; Albera C; Behr J; Wuyts WA; Kirchgaessler KU; Stauffer JL; Morgenthien E; Chou W; Limb SL; Noble PW
    Respir Med; 2019 Jul; 153():44-51. PubMed ID: 31153107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone.
    Kreuter M; Spagnolo P; Wuyts W; Renzoni E; Koschel D; Bonella F; Maher TM; Kolb M; Weycker D; Kirchgässler KU; Costabel U
    Respiration; 2017; 93(6):415-423. PubMed ID: 28399537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the Therapeutic Response to Pirfenidone in Idiopathic Pulmonary Fibrosis: Can We Do Better than with Forced Vital Capacity Alone?
    Hosein K; Le J; Mura M
    Lung; 2017 Feb; 195(1):101-105. PubMed ID: 27858160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.
    Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ
    Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis.
    Xie Y; Jiang H; Zhang Q; Mehrotra S; Abel PW; Toews ML; Wolff DW; Rennard S; Panettieri RA; Casale TB; Tu Y
    Respir Res; 2016 Aug; 17(1):103. PubMed ID: 27549302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects.
    Overed-Sayer C; Miranda E; Dunmore R; Liarte Marin E; Beloki L; Rassl D; Parfrey H; Carruthers A; Chahboub A; Koch S; Güler-Gane G; Kuziora M; Lewis A; Murray L; May R; Clarke D
    Thorax; 2020 Sep; 75(9):754-763. PubMed ID: 32709610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study.
    Tzouvelekis A; Ntolios P; Karampitsakos T; Tzilas V; Anevlavis S; Bouros E; Steiropoulos P; Koulouris N; Stratakos G; Froudarakis M; Bouros D
    Pulm Pharmacol Ther; 2017 Oct; 46():48-53. PubMed ID: 28843616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
    Noble PW; Albera C; Bradford WZ; Costabel U; Glassberg MK; Kardatzke D; King TE; Lancaster L; Sahn SA; Szwarcberg J; Valeyre D; du Bois RM;
    Lancet; 2011 May; 377(9779):1760-9. PubMed ID: 21571362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pirfenidone treatment of idiopathic pulmonary fibrosis.
    Azuma A
    Ther Adv Respir Dis; 2012 Apr; 6(2):107-14. PubMed ID: 22333982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis.
    Lehmann M; Buhl L; Alsafadi HN; Klee S; Hermann S; Mutze K; Ota C; Lindner M; Behr J; Hilgendorff A; Wagner DE; Königshoff M
    Respir Res; 2018 Sep; 19(1):175. PubMed ID: 30219058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: the PolExPIR study.
    Majewski S; Białas AJ; Buchczyk M; Gomółka P; Górska K; Jagielska-Len H; Jarzemska A; Jassem E; Jastrzębski D; Kania A; Koprowski M; Krenke R; Kuś J; Lewandowska K; Martusewicz-Boros MM; Roszkowski-Śliż K; Siemińska A; Sładek K; Sobiecka M; Szewczyk K; Tomczak M; Tomkowski W; Wiatr E; Ziora D; Żołnowska B; Piotrowski WJ
    BMC Pulm Med; 2020 May; 20(1):122. PubMed ID: 32366291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis.
    Ley B; Swigris J; Day BM; Stauffer JL; Raimundo K; Chou W; Collard HR
    Am J Respir Crit Care Med; 2017 Sep; 196(6):756-761. PubMed ID: 28471697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.
    Costabel U; Albera C; Bradford WZ; Hormel P; King TE; Noble PW; Sahn SA; Valeyre D; du Bois RM
    Sarcoidosis Vasc Diffuse Lung Dis; 2014 Oct; 31(3):198-205. PubMed ID: 25363219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.
    Noble PW; Albera C; Bradford WZ; Costabel U; du Bois RM; Fagan EA; Fishman RS; Glaspole I; Glassberg MK; Lancaster L; Lederer DJ; Leff JA; Nathan SD; Pereira CA; Swigris JJ; Valeyre D; King TE
    Eur Respir J; 2016 Jan; 47(1):243-53. PubMed ID: 26647432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.